For subscribers
US Medicare to reimburse use of cancer-matching service developed in Singapore
Sign up now: Get ST's newsletters delivered to your inbox
The cancer-matching service is able to match lung cancers to a targeted drug, should there be one.
PHOTO ILLUSTRATION: PIXABAY
Follow topic:
SINGAPORE – Several cancer-related organisations in Singapore are excited with the recent announcement that Medicare, the United States federal health insurance programme, will reimburse patients with advanced lung cancer who use a technology developed in Singapore.
Lucence, which has headquarters in Singapore and the US, said: “This approval establishes Lucence as the first and only Asian-headquartered healthcare services company to secure United States national insurance coverage.”
